🎉 M&A multiples are live!
Check it out!

Telomir Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Telomir Pharmaceuticals and similar public comparables like Galapagos, Julphar, and Vivoryon Therapeutics.

Telomir Pharmaceuticals Overview

About Telomir Pharmaceuticals

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer’s disease, osteoarthritis, and others.


Founded

2021

HQ

United States of America
Employees

5

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$81.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Telomir Pharmaceuticals Financials

Telomir Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Telomir Pharmaceuticals achieved revenue of n/a and an EBITDA of -$12.2M.

Telomir Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Telomir Pharmaceuticals valuation multiples based on analyst estimates

Telomir Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$11.4M -$12.2M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$0.9M -$13.1M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a $0.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Telomir Pharmaceuticals Stock Performance

As of April 15, 2025, Telomir Pharmaceuticals's stock price is $3.

Telomir Pharmaceuticals has current market cap of $81.5M, and EV of $81.6M.

See Telomir Pharmaceuticals trading valuation data

Telomir Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$81.6M $81.5M XXX XXX XXX XXX $-0.51

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Telomir Pharmaceuticals Valuation Multiples

As of April 15, 2025, Telomir Pharmaceuticals has market cap of $81.5M and EV of $81.6M.

Telomir Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Telomir Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Telomir Pharmaceuticals and 10K+ public comps

Telomir Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $81.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -6.7x XXX XXX XXX
P/E -4.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -16.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Telomir Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Telomir Pharmaceuticals Valuation Multiples

Telomir Pharmaceuticals's NTM/LTM revenue growth is Infinity%

Telomir Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.4M for the same period.

Over next 12 months, Telomir Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Telomir Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Telomir Pharmaceuticals and other 10K+ public comps

Telomir Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Telomir Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Telomir Pharmaceuticals M&A and Investment Activity

Telomir Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Telomir Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Telomir Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Telomir Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Telomir Pharmaceuticals

When was Telomir Pharmaceuticals founded? Telomir Pharmaceuticals was founded in 2021.
Where is Telomir Pharmaceuticals headquartered? Telomir Pharmaceuticals is headquartered in United States of America.
How many employees does Telomir Pharmaceuticals have? As of today, Telomir Pharmaceuticals has 5 employees.
Who is the CEO of Telomir Pharmaceuticals? Telomir Pharmaceuticals's CEO is Mr. Erez Aminov.
Is Telomir Pharmaceuticals publicy listed? Yes, Telomir Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Telomir Pharmaceuticals? Telomir Pharmaceuticals trades under TELO ticker.
When did Telomir Pharmaceuticals go public? Telomir Pharmaceuticals went public in 2024.
Who are competitors of Telomir Pharmaceuticals? Similar companies to Telomir Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Telomir Pharmaceuticals? Telomir Pharmaceuticals's current market cap is $81.5M
Is Telomir Pharmaceuticals profitable? Yes, Telomir Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.